ストックスクリーナーアプリを入手
4.58
1.29%
-0.06
前日終値:
$4.64
開ける：
$4.73
24時間の取引高:
404.58K
Relative Volume:
1.07
時価総額：
$110.65M
収益：
$68.38M
当期純損益:
$-20.17M
株価収益率:
-5.1816
EPS:
-0.8839
ネットキャッシュフロー:
$-14.13M
1週間 パフォーマンス:
+0.88%
1か月 パフォーマンス:
-0.87%
6か月 パフォーマンス:
-25.29%
1年 パフォーマンス:
-34.48%
1日の値動き範囲:
$4.53
$5.01
1週間の範囲:
$4.285
$5.01
52週間の値動き範囲:
$2.59
$12.23
Exagen Inc Stock (XGN) Company Profile
Compare XGN vs TMO, DHR, IDXX, A, NTRA
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XGN
Exagen Inc
|
4.58 | 112.10M | 68.38M | -20.17M | -14.13M | -0.8839 |
TMO
Thermo Fisher Scientific Inc
|
513.03 | 187.95B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
196.19 | 136.75B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
551.50 | 43.78B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
136.01 | 38.27B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
261.91 | 37.34B | 2.50B | -226.32M | 71.51M | -1.6412 |
Exagen Inc Stock (XGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-11 | 開始されました | B. Riley Securities | Buy |
| 2025-07-30 | アップグレード | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2025-07-23 | 開始されました | Craig Hallum | Buy |
| 2022-08-05 | ダウングレード | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2021-10-15 | 再開されました | Cowen | Outperform |
| 2021-04-15 | 開始されました | Canaccord Genuity | Buy |
| 2020-11-10 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2020-10-08 | 開始されました | BTIG Research | Buy |
| 2020-06-02 | 再開されました | Cantor Fitzgerald | Overweight |
| 2019-10-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-10-14 | 開始されました | Cowen | Outperform |
| 2019-10-14 | 開始されました | William Blair | Outperform |
すべてを表示
Exagen Inc (XGN) 最新ニュース
Enterprise value to revenue forward of Exagen Inc. – NASDAQ:XGN - TradingView
Enterprise value to revenue forward of Exagen Inc. – BOATS:XGN - TradingView
Exagen, Inc. Actuals & Estimates (NASDAQ:XGN) - TradingView
Exagen sets dates for second-quarter results, shares watched around Nasdaq listing - Ad-hoc-news.de
E08A Forecast — Price Target — Prediction for 2027 - TradingView
XGN Forecast — Price Target — Prediction for 2027 - TradingView
XGN Initiates Coverage On Exagen -- Roth Capital Assigns Buy Rat - GuruFocus
Exagen (XGN) Gains Buy Rating with $8 Price Target from Analyst - GuruFocus
Form 4 Exagen Inc For: 24 June By Investing.com - Investing.com Nigeria
Exagen Inc (XGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Form 4 Exagen Inc For: 22 June By Investing.com - Investing.com Australia
Exagen (XGN) director Scott Kahn receives 37,500 stock options grant - Stock Titan
Exagen (XGN) director granted 37,500 stock options at $4.31 strike - Stock Titan
Exagen (XGN) director Frank Stokes receives 37,500 stock options at $4.31 - Stock Titan
Exagen StockSunday background on autoimmune diagnostics specialist - Ad-hoc-news.de
Exagen advances use of new RA biomarkers to refine patient risk assessment - Traders Union
Exagen Inc (XGN) Institutional Confidence - TradingKey
Exagen (XGN) Stock Draws Fresh Price Target Split After Analysts Trim Targets - Yahoo Finance
Exagen Inc (XGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Exagen Inc (XGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Exagen Inc (XGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Exagen Inc (XGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Exagen Inc (XGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Exagen Inc (XGN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Exagen Inc (XGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Exagen Inc. (XGN) Q1 2026 Earnings: Adjusted Loss Narrows, Stock Gains in AftermathSegment Revenue Breakdown - newsline.com
Exagen Shareholders Approve Directors, Auditor and Pay Package - The Globe and Mail
Exagen | 8-K: Current report - Moomoo
Exagen (NASDAQ: XGN) shareholders approve directors, auditor and say-on-pay - Stock Titan
Exagen Company Profile & Introduction - Moomoo
XGN Q1 2026 Earnings: EPS Beats Estimates Despite Stock DeclineRevenue Surprise History - newsline.com
Exagen Inc. Q1 2026 Earnings: EPS Surprise Lifts but Revenue Disclosure Gap Weighs on SharesMargin Compression Risk - newsline.com
Exagen Inc. (XGN) Plunges 9.4% – Key Support Levels in Focus After Sharp SelloffIV Spike - newsline.com
Exagen study shows lupus test identifies 25% more patients By Investing.com - Investing.com South Africa
Exagen study shows lupus test identifies 25% more patients - Investing.com
Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus - GlobeNewswire
Exagen Inc. (XGN) Q1 2026 Earnings: EPS Beats Estimates by 15.15%, Revenue Details Withheld, Stock DeclinesBook Value Growth - The Legal Advocate
Record revenue growth and higher test pricing keep Exagen (XGN) in focus despite ongoing losses - MSN
How much upside is left in Exagen (XGN)? Wall Street analysts think 73.05% - MSN
Exagen Inc. (XGN) reports Q1 loss, beats revenue estimates - MSN
How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05% - Yahoo Finance
Parian Ultreia reports 5.3% stake in Exagen (NASDAQ: XGN) - Stock Titan
Exagen Inc. Q1 2026 Earnings: EPS Beat Surprises, but Revenue Details AbsentEstimate Accuracy - The Legal Advocate
XGN Q1 2026 Earnings: EPS Beat Highlights Cost Discipline Amid Revenue UncertaintyEarnings Weakness Phase - Newser
Exagen Inc. (XGN) Holds Steady Near Support Amid Low VolatilityLiquidity Sweep - The Legal Advocate
Exagen Inc. (XGN) Inches Lower as Shares Test Key Support Near $4.05Institutional Volume - The Legal Advocate
William Blair Maintains Exagen(XGN.US) With Buy Rating - Moomoo
Exagen Inc (XGN) 財務データ
収益
当期純利益
現金流量
EPS
1.76%
0.62%
大文字化:
|
ボリューム (24 時間):